Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Exelixis

Biotech & Life Sciences · San Francisco, United States · Founded 1994 · IPO 2000 Unicorn

Exelixis works on discovering, developing, and commercializing therapies for the treatment of cancer

Valuation
$10B
Market cap · May/2026
Revenue
$2.32B
Latest reported FY
EBITDA
$1.09B
Latest reported FY

Investors

10 investors on Exelixis's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 4 investors entered at this stage
Atlas Venture
PaineWebber
Stelios Papadopoulos
Oxford Bioscience Partners
Series A 4 investors entered at this stage
Hambrecht & Quist Capital Management
Domain Associates
Pfizer
Advent International
Series B+ 2 investors entered at this stage
University of California
Berkeley

Global footprint

Where Exelixis has talent and traffic

AI talent share
0.5% of workforce is AI talent
(7 of 1,521 staff)
Core AI20.13%
Other AI50.33%
Non-AI workforce1,51499.54%
Workforce by country
13 countries with
team presence
🇺🇸 United States98.1%
🇮🇳 India0.5%
🇫🇷 France0.3%
🇧🇩 Bangladesh0.2%
🇺🇦 Ukraine0.1%
Top 5 of 13 shown
Web traffic by country
36K monthly visits
across markets
🇺🇸 United States76.1%
🇮🇳 India11.7%
🇨🇦 Canada5.3%
🇬🇧 United Kingdom2.8%
🇩🇪 Germany1.7%
Top 5 markets shown

Patent intelligence

$161M patent portfolio · 108 active families

Estimated portfolio value
$161M
1.5% of market cap · 12.6× smaller than top peer Ablynx ($2B)
108 active patent families
Where Exelixis innovates Molecular biologyDiseasePharmaceutical medicineMedicinal chemistryPharmacology

Where Exelixis concentrates vs peers

Each axis is a top-10 topic across Exelixis and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Exelixis's 4 investments and acquisitions.

Every disclosed deal where Exelixis appeared as a backer or acquirer, 2000–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across Exelixis's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Exelixis deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Exelixis's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        What the market is saying about Exelixis

        An AI-synthesized read of the highest-engagement posts about Exelixis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Exelixis on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.